New pilot study links pomegranate to baby brain development

Consuming pomegranate juice daily during pregnancy may protect brain development and brain connectivity in babies diagnosed with intrauterine growth restriction (IUGR).

The exploratory study, supported by the National Institute of Health Grants and The Foundation for Barnes-Jewish Hospital has already lead to a second, larger clinical trial at the Brigham to validate these findings. The protective effects of polyphenols against neurodegenerative diseases have been explored in various scientific studies but to date, no clinical studies have evaluated the potential effects of giving pregnant women pomegranate juice to support the brains of at-risk newborns.

Intrauterine growth restriction (IUGR) refers to a condition in which an unborn is smaller than it should because it is not growing at a normal rate inside the womb. Delayed growth puts the baby at risk of certain health problems during pregnancy, delivery and after birth. A common cause is a problem with the placenta, which carries oxygen and nutrients to the baby, including the brain.

More information about the Pilot study can be found here.


Pomella® pomegranate extract is a patented, clinically researched pomegranate extract developed in collaboration with a major research university located in California. Standardized to punicalagins (which are water-soluble and highly bioavailable) along with the natural spectrum of pomegranate fruit polyphenols. For more information, visit our dedicated page or contact us.